Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Texas Interprofessional Pharmacogenomics (IPGx)
Sponsor: Texas A&M University
Summary
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
Official title: The Texas Interprofessional Pharmacogenomics (IPGx) PILOT Cohort
Key Details
Gender
All
Age Range
45 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2021-12-15
Completion Date
2027-11
Last Updated
2025-09-12
Healthy Volunteers
Not specified
Conditions
Locations (1)
The Interprofessional Pharmacogenomics (IPGx) Clinic
Bryan, Texas, United States